Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT00003934
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Combination Chemotherapy in Treating Women With Resected Breast Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-09
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Registration Number
- NCT00033683
- Locations
- 🇬🇧
St. Georges Hospital Medical School, London, England, United Kingdom
🇬🇧Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, United Kingdom
🇬🇧Leicester Royal Infirmary, Leicester, England, United Kingdom
S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-11-01
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT00041132
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 400
- Registration Number
- NCT00003215
- Locations
- 🇨🇭
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
🇨🇭Inselspital, Bern, Bern, Switzerland
🇨🇭Ratisches Kantons und Regionalspital, Chur, Switzerland
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-09-21
- Target Recruit Count
- 202
- Registration Number
- NCT00003838
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00023998
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: prednisoneDrug: vincristine sulfateDrug: daunorubicin hydrochlorideDrug: asparaginaseDrug: methotrexateDrug: cyclophosphamideDrug: cytarabineDrug: mercaptopurineDrug: leucovorin calciumDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: thioguanineRadiation: radiation therapyDrug: pegaspargaseOther: pharmacological studyDrug: nelarabineOther: laboratory biomarker analysis
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT00016302
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- Conditions
- Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Monoblastic Leukemia (M5a)Childhood Acute Monocytic Leukemia (M5b)Childhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Myeloblastic Leukemia Without Maturation (M1)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic SyndromesChronic Myelomonocytic Leukemiade Novo Myelodysplastic Syndromes
- Interventions
- Drug: daunorubicin hydrochlorideDrug: asparaginaseDrug: therapeutic hydrocortisoneRadiation: 3-dimensional conformal radiation therapyDrug: fludarabine phosphateProcedure: allogeneic bone marrow transplantationBiological: filgrastimDrug: cytarabineDrug: idarubicinDrug: dexamethasoneBiological: aldesleukinDrug: thioguanineDrug: etoposideDrug: methotrexateDrug: cyclophosphamideDrug: busulfan
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00002798
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Bone Marrow Transplant Plus Cyclophosphamide and Total-Body Irradiation in Treating Patients With Hematologic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Temple University
- Target Recruit Count
- 10
- Registration Number
- NCT00002809
- Locations
- 🇺🇸
Fox Chase-Temple Cancer Center, Philadelphia, Pennsylvania, United States
Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00049634
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.